REVIEW
Temozolomide in aggressive pituitary adenomas and carcinomas
Leon D. OrtizI, Luis V. SyroII,
, Bernd W. Scheithauer (in memoriam)III, Fabio RotondoIV, Humberto UribeV, Camilo E. FadulVI, Eva HorvathIV, Kalman KovacsIV
Corresponding author
I Instituto de Cancerologia, Clinica Las Americas, Division of Neuro-oncology, Medellin, Colombia.
II Hospital Pablo Tobon Uribe and Clinica Medellin, Department of Neurosurgery, Medellin, Colombia.
III Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA.
IV University of Toronto, St Michael's Hospital, Department of Laboratory Medicine, Toronto, Ontario, Canada.
V Clinica SOMA, Department of Neurosurgery, Medellin, Colombia.
VI Dartmouth Hitchcock Medical Center, Department of Medicine (Section of Hematology/Oncology) and Neurology, Lebanon, New Hampshire, USA.
Read
545
Timeswas read the article
302
Total PDF
243
Total HTML
Share statistics
array:24 [ "pii" => "S1807593222024061" "issn" => "18075932" "doi" => "10.6061/clinics/2012(Sup01)20" "estado" => "S300" "fechaPublicacion" => "2012-04-01" "aid" => "2406" "copyright" => "CLINICS" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by-nc/3.0/" "subdocumento" => "rev" "cita" => "Clinics. 2012;67 Supl 1:119-23" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S1807593222024073" "issn" => "18075932" "doi" => "10.6061/clinics/2012(Sup01)21" "estado" => "S300" "fechaPublicacion" => "2012-04-01" "aid" => "2407" "copyright" => "CLINICS" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by-nc/3.0/" "subdocumento" => "rev" "cita" => "Clinics. 2012;67 Supl 1:125-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">REVIEW</span>" "titulo" => "Kinase inhibitors for advanced medullary thyroid carcinoma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "125" "paginaFinal" => "129" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Martin Schlumberger, Marie-Hélène Massicotte, Camila L. Nascimento, Cécile Chougnet, Eric Baudin, Sophie Leboulleux" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Martin" "apellidos" => "Schlumberger" ] 1 => array:2 [ "nombre" => "Marie-Hélène" "apellidos" => "Massicotte" ] 2 => array:2 [ "nombre" => "Camila L." "apellidos" => "Nascimento" ] 3 => array:2 [ "nombre" => "Cécile" "apellidos" => "Chougnet" ] 4 => array:2 [ "nombre" => "Eric" "apellidos" => "Baudin" ] 5 => array:2 [ "nombre" => "Sophie" "apellidos" => "Leboulleux" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222024073?idApp=UINPBA00004N" "url" => "/18075932/00000067000000S1/v1_202212010649/S1807593222024073/v1_202212010649/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S180759322202405X" "issn" => "18075932" "doi" => "10.6061/clinics/2012(Sup01)19" "estado" => "S300" "fechaPublicacion" => "2012-04-01" "aid" => "2405" "copyright" => "CLINICS" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by-nc/3.0/" "subdocumento" => "rev" "cita" => "Clinics. 2012;67 Supl 1:113-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">REVIEW</span>" "titulo" => "Multiple endocrine neoplasia type 2: achievements and current challenges" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "113" "paginaFinal" => "118" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 474 "Ancho" => 662 "Tamanyo" => 45935 ] ] "descripcion" => array:1 [ "en" => "<p id="spara10" class="elsevierStyleSimplePara elsevierViewall">Multigenerational Ethnic German C634R Family from Romania.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Andreas Machens, Henning Dralle" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Andreas" "apellidos" => "Machens" ] 1 => array:2 [ "nombre" => "Henning" "apellidos" => "Dralle" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S180759322202405X?idApp=UINPBA00004N" "url" => "/18075932/00000067000000S1/v1_202212010649/S180759322202405X/v1_202212010649/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">REVIEW</span>" "titulo" => "Temozolomide in aggressive pituitary adenomas and carcinomas" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "119" "paginaFinal" => "123" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Leon D. Ortiz, Luis V. Syro, Bernd W. Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E. Fadul, Eva Horvath, Kalman Kovacs" "autores" => array:8 [ 0 => array:3 [ "nombre" => "Leon D." "apellidos" => "Ortiz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">I</span>" "identificador" => "aff1" ] ] ] 1 => array:4 [ "nombre" => "Luis V." "apellidos" => "Syro" "email" => array:1 [ 0 => "lvsyro@une.net.co" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">II</span>" "identificador" => "aff2" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor1" ] ] ] 2 => array:4 [ "nombre" => "Bernd W." "apellidos" => "Scheithauer" "sufijo" => "(in memoriam)" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">III</span>" "identificador" => "aff3" ] ] ] 3 => array:3 [ "nombre" => "Fabio" "apellidos" => "Rotondo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">IV</span>" "identificador" => "aff4" ] ] ] 4 => array:3 [ "nombre" => "Humberto" "apellidos" => "Uribe" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">V</span>" "identificador" => "aff5" ] ] ] 5 => array:3 [ "nombre" => "Camilo E." "apellidos" => "Fadul" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">VI</span>" "identificador" => "aff6" ] ] ] 6 => array:3 [ "nombre" => "Eva" "apellidos" => "Horvath" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">IV</span>" "identificador" => "aff4" ] ] ] 7 => array:3 [ "nombre" => "Kalman" "apellidos" => "Kovacs" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">IV</span>" "identificador" => "aff4" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => "Instituto de Cancerologia, Clinica Las Americas, Division of Neuro-oncology, Medellin, Colombia." "etiqueta" => "I" "identificador" => "aff1" ] 1 => array:3 [ "entidad" => "Hospital Pablo Tobon Uribe and Clinica Medellin, Department of Neurosurgery, Medellin, Colombia." "etiqueta" => "II" "identificador" => "aff2" ] 2 => array:3 [ "entidad" => "Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA." "etiqueta" => "III" "identificador" => "aff3" ] 3 => array:3 [ "entidad" => "University of Toronto, St Michael's Hospital, Department of Laboratory Medicine, Toronto, Ontario, Canada." "etiqueta" => "IV" "identificador" => "aff4" ] 4 => array:3 [ "entidad" => "Clinica SOMA, Department of Neurosurgery, Medellin, Colombia." "etiqueta" => "V" "identificador" => "aff5" ] 5 => array:3 [ "entidad" => "Dartmouth Hitchcock Medical Center, Department of Medicine (Section of Hematology/Oncology) and Neurology, Lebanon, New Hampshire, USA." "etiqueta" => "VI" "identificador" => "aff6" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "Tel.: 57 4 231 9099" ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="cesec10" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle20">INTRODUCTION</span><p id="para10" class="elsevierStylePara elsevierViewall">Patients with aggressive pituitary adenomas are difficult to clinically manage. Frequently, these adenomas are large, rapidly growing and invasive to their surroundings. These tumors also present problems due to incomplete resection and recurrence. Reoperation, pharmacological treatment and radiotherapy are routinely employed, often in combination. Nevertheless, many patients experience tumor regrowth (<a class="elsevierStyleCrossRef" href="#bib1">1</a>). Endocrinologically active adenomas, particularly prolactin (PRL)- and growth hormone (GH)-producing tumors, may become resistant to medical therapy, thus requiring multiple resections. Radiation and conventional chemotherapy are often employed in an attempt to achieve local tumor control, but the results are often disappointing.</p><p id="para20" class="elsevierStylePara elsevierViewall">Pituitary carcinomas are rare and present particular diagnostic and therapeutic challenges. All of these carcinomas are of large size, invasive and associated with craniospinal and/or systemic metastases. Multiple treatment approaches, including surgery, external beam radiotherapy, radiosurgery, adjuvant pharmacological therapy and various chemotherapeutic approaches, are palliative at best, achieving only temporary effects (<a class="elsevierStyleCrossRef" href="#bib2">2</a>),(<a class="elsevierStyleCrossRef" href="#bib3">3</a>). Progression of the disease after the diagnosis of pituitary carcinoma is variable but often inexorable. Approximately 75% of patients with systemic metastasis die within 1 year of documented spread (<a class="elsevierStyleCrossRef" href="#bib4">4</a>).</p><p id="para30" class="elsevierStylePara elsevierViewall">Recent publications have reported the efficacy of temozolomide for treating aggressive pituitary adenomas and carcinomas (<a class="elsevierStyleCrossRefs" href="#bib5">5–29</a>). In this review, we discuss the indications, results and side effects of temozolomide therapy.</p><span id="cesec20" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle30">Temozolomide</span><p id="para40" class="elsevierStylePara elsevierViewall">Temozolomide is a second-generation alkylating chemotherapeutic agent related to a series of imidazotetrazines that were originally synthesized in 1987 (<a class="elsevierStyleCrossRef" href="#bib30">30</a>). Orally administered, it readily crosses the blood-brain barrier. At physiological pH, it undergoes rapid conversion to methyl-triazeno-imidazole-carboxamide (MTIC), the active agent. It exerts its cytotoxic effects through methylation of DNA at the <span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span> position of guanine (<a class="elsevierStyleCrossRef" href="#bib31">31</a>), which then mispairs with thymine during the next cycle of DNA replication. The sequence of mismatch-repair events lead to apoptosis.</p><p id="para50" class="elsevierStylePara elsevierViewall">Temozolomide is accepted as an essential component of adjuvant therapy for the treatment of glioblastoma multiforme and other tumors of the central nervous system (<a class="elsevierStyleCrossRefs" href="#bib32">32–34</a>). Recent reports indicate its efficacy for treating advanced-stage malignant neuroendocrine neoplasia (<a class="elsevierStyleCrossRef" href="#bib35">35</a>), melanoma (<a class="elsevierStyleCrossRef" href="#bib36">36</a>),(<a class="elsevierStyleCrossRef" href="#bib37">37</a>), and colorectal carcinoma (<a class="elsevierStyleCrossRef" href="#bib38">38</a>).</p><p id="para60" class="elsevierStylePara elsevierViewall">The standard therapeutic dose of temozolomide is 150–200 mg/m<span class="elsevierStyleSup">2</span> for five of every 28 days (5/28). Depletion of <span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span>-methylguanine-DNA methyltransferase (MGMT) has been proposed as a means of tumor response to temozolomide (<a class="elsevierStyleCrossRef" href="#bib39">39</a>). Experimental and clinical data have shown that the temozolomide response is schedule-dependent and that alternative dosing regimens may enhance its efficacy (<a class="elsevierStyleCrossRef" href="#bib40">40</a>),(<a class="elsevierStyleCrossRef" href="#bib41">41</a>). The anti-angiogenic effect of temozolomide can be optimized by administering low doses of the drug on a frequent or continuous schedule without extended interruptions (i.e., “metronomic” chemotherapy). Temozolomide can also be administered on a continuous, daily metronomic schedule, thus achieving MGMT depletion and improving the clinical response. This dose is generally 50 mg/m<span class="elsevierStyleSup">2</span>/day without interruption (28/28). Other temozolomide schedules recommend administration every other week (7/14) or a 21-consecutive-day regimen that is administered every 28 days (21/28). Both are considered dose-dense regimens based on the Norton-Simon model of cell proliferation, which states that a dose of chemotherapy will have a fixed cell-kill rate regardless of the size of the tumor (<a class="elsevierStyleCrossRef" href="#bib39">39</a>). Thus, decreasing the time interval between doses (i.e., increasing the dose density) improves efficacy by minimizing the opportunity for cellular regrowth between cycles (<a class="elsevierStyleCrossRef" href="#bib41">41</a>). In these dose-dense regimens, temozolomide is administered at a dose of 150 mg/m<span class="elsevierStyleSup">2</span>/day for 7 days every other week (7/14) or at a dose of 85–100 mg/m<span class="elsevierStyleSup">2</span>/day for 21 consecutive days (21/28) (<a class="elsevierStyleCrossRef" href="#bib40">40</a>). In reported pituitary cases, temozolomide was administered as monotherapy in all but three cases. The standard 5/28 regimen was used in almost all instances except in the series of Bush et al. (<a class="elsevierStyleCrossRef" href="#bib23">23</a>), in which a dose-dense, 21/28 schedule was used, and one case progressed to carcinoma, which was then treated using the metronomic 28/28 schedule (<a class="elsevierStyleCrossRef" href="#bib29">29</a>). Temozolomide absorption is only minimally affected by food. Furthermore, no serious side effects have been reported. Common, non-hematological adverse effects are present, including nausea, vomiting, fatigue, headache and constipation, most of which are mild to moderate in severity.</p><p id="para70" class="elsevierStylePara elsevierViewall">As previously stated, MGMT is a DNA repair protein that reverses the effects of temozolomide therapy (<a class="elsevierStyleCrossRef" href="#bib42">42</a>) by removing alkylating adducts, thereby counteracting its effects (<a class="elsevierStyleCrossRef" href="#bib43">43</a>) and conferring resistance to the agent (<a class="elsevierStyleCrossRef" href="#bib44">44</a>). Low-level expression in a wide variety of human tumors is thought to result from epigenetic silencing by hypermethylation of the <span class="elsevierStyleItalic">MGMT</span> gene promoter (<a class="elsevierStyleCrossRef" href="#bib44">44</a>),(<a class="elsevierStyleCrossRef" href="#bib45">45</a>). Low-level <span class="elsevierStyleItalic">MGMT</span> expression is a predictive marker of a favorable clinical outcome in patients with temozolomide-treated glioblastomas (<a class="elsevierStyleCrossRefs" href="#bib46">46–48</a>). Herein, we extend this observation to aggressive adenohypophysial tumors.</p></span><span id="cesec30" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle40">Pituitary adenomas</span><p id="para80" class="elsevierStylePara elsevierViewall">The first temozolomide-treated pituitary adenoma patient was reported in 2006 (<a class="elsevierStyleCrossRef" href="#bib7">7</a>),(<a class="elsevierStyleCrossRef" href="#bib8">8</a>). The tumor, which was investigated using histological, immunohistochemical and electron microscopic techniques, showed significant posttherapeutic effects, including hemorrhage, necrosis, focal fibrosis, reduced mitotic activity, Ki-67 labeling and, surprisingly, neuronal transformation. MGMT immunoexpression was completely absent. Subsequently, the case of a 41-year-old patient with an aggressive silent subtype 2 corticotroph adenoma was reported (<a class="elsevierStyleCrossRef" href="#bib10">10</a>). It showed no morphological changes after temozolomide treatment. The tumor cell nuclei were immunopositive for MGMT. Based upon these results, it was suggested that MGMT immunoexpression may predict the responsiveness of temozolomide therapy (<a class="elsevierStyleCrossRef" href="#bib10">10</a>).</p><p id="para90" class="elsevierStylePara elsevierViewall">To the best of our knowledge, to date 30 cases of pituitary adenoma have been treated with temozolomide (<a class="elsevierStyleCrossRef" href="#bib7">7-16</a>),(<a class="elsevierStyleCrossRef" href="#bib8">18-20</a>),(<a class="elsevierStyleCrossRef" href="#bib9">22-26</a>),(<a class="elsevierStyleCrossRef" href="#bib10">28</a>),. Patient ages varied from 20 to 71 years (mean: 51 years). Aside from one tumor that was incidentally discovered in a patient with concomitant glioblastoma multiforme, all tumors were morphologically studied. The group included ten adrenocorticotropic hormone (ACTH)-producing tumors, nine PRL-producing tumors, seven clinically non-functioning adenomas, two silent ACTH adenomas, and two GH-producing adenomas. The time between clinical presentation and onset of temozolomide treatment was between 2 and 23 years (mean: 10.7 years). Twenty-six of the 30 tumors had been irradiated previously. Aside from the incidentally discovered tumor in one patient, all other patients had undergone at least one operative procedure, the number ranging from 0 to 6 procedures (mean: 2.7). The response rate was 60% (18/30 patients). Debono et al. (<a class="elsevierStyleCrossRef" href="#bib11">11</a>) reported the first case of a pituitary adenoma associated with multiple endocrine neoplasia type 1 (MEN1) that was treated with temozolomide. The 47-year-old man had primary hyperparathyroidism and a lesion at the head of the pancreas. Genetic analysis confirmed MEN1. The dopamine-resistant, prolactin-producing pituitary adenoma responded dramatically to temozolomide, demonstrating clinical, biochemical, and radiological improvements.</p><p id="para100" class="elsevierStylePara elsevierViewall">MGMT immunoexpression was documented in 23 of the 30 patients. A high level of labeling was seen in six instances, an intermediate level in six instances, and a low level in 11 instances. Only one of six patients with high MGMT immunoexpression responded to temozolomide. Two tumors with intermediate MGMT immunoexpression did not respond, whereas nine of the 11 tumors with low-level MGMT immunoexpression responded favorably.</p></span><span id="cesec40" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle50">Pituitary carcinomas</span><p id="para110" class="elsevierStylePara elsevierViewall">Pituitary carcinomas are difficult to manage given their relentless growth and metastatic spread, despite the effects of multimodality therapy. The latter includes repeated surgeries, pharmacological manipulation, radiotherapy, and conventional chemotherapy (<a class="elsevierStyleCrossRef" href="#bib3">3</a>),(<a class="elsevierStyleCrossRef" href="#bib49">49</a>), including various combinations of <span class="elsevierStyleItalic">cis</span>-platinum, etoposide and/or paclitaxel, but these have failed to achieve favorable clinical responses (<a class="elsevierStyleCrossRef" href="#bib2">2</a>).</p><p id="para120" class="elsevierStylePara elsevierViewall">Initial reports of the successful use of temozolomide to treat pituitary carcinomas appeared in 2006 (<a class="elsevierStyleCrossRef" href="#bib5">5</a>),(<a class="elsevierStyleCrossRef" href="#bib6">6</a>). To date, 16 cases have been treated (<a class="elsevierStyleCrossRef" href="#bib5">5</a>),(<a class="elsevierStyleCrossRef" href="#bib6">6</a>),(<a class="elsevierStyleCrossRef" href="#bib13">13</a>),(<a class="elsevierStyleCrossRef" href="#bib16">16</a>),(<a class="elsevierStyleCrossRef" href="#bib17">17</a>),(<a class="elsevierStyleCrossRef" href="#bib21">21-23</a>),. The time between disease presentation to temozolomide administration was 5–23 years (mean: 10.7 years). The group included nine PRL-producing tumors, five ACTH-producing tumors, three clinically non-functional tumors, and three silent corticotroph carcinomas. Eleven of the 16 patients (69%) experienced a clinical and radiological response to temozolomide. Assessment of MGMT immunoexpression was only available in 11 patients; only one patient with high-level immunoexpression responded to treatment.</p></span><span id="cesec50" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle60">Morphological changes</span><p id="para130" class="elsevierStylePara elsevierViewall">Morphological comparisons of pathology before and after temozolomide treatment were performed in three cases: all were patients with adenomas. One was a non-responder who exhibited no changes (<a class="elsevierStyleCrossRef" href="#bib10">10</a>) and two were responders (<a class="elsevierStyleCrossRef" href="#bib8">8</a>),(<a class="elsevierStyleCrossRef" href="#bib23">23</a>) whose tumors after treatment demonstrated hemorrhage, necrosis, focal fibrosis, inflammatory infiltrates, fewer mitoses, and a low Ki-67 labeling index, as well as neuronal transformation. The latter is considered to be a metaplastic phenomenon and has been observed in a variety of untreated endocrine neoplasms, including GH cell adenomas (<a class="elsevierStyleCrossRef" href="#bib50">50</a>).</p></span></span><span id="cesec60" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle70">DISCUSSION</span><span id="cesec70" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle80">Response to treatment</span><p id="para140" class="elsevierStylePara elsevierViewall">In patients who respond to temozolomide, three basic patterns of radiographic changes are seen on MRI: tumor necrosis and hemorrhage (<a class="elsevierStyleCrossRef" href="#bib7">7</a>),(<a class="elsevierStyleCrossRef" href="#bib8">8</a>), cystic change (<a class="elsevierStyleCrossRef" href="#bib19">19</a>), and shrinkage (<a class="elsevierStyleCrossRef" href="#bib9">9</a>),. Such changes may be seen as early as two months after the onset of treatment.</p><p id="para150" class="elsevierStylePara elsevierViewall">In the tumors that respond to temozolomide, the clinical response is rapid and associated with prompt decreases in chiasmatic compression and mass effects. In patients with endocrine-active PRL- and ACTH-producing tumors, an almost immediate reduction in plasma hormone levels becomes apparent after commencement of therapy. Thus, it is possible to quickly evaluate the treatment response.</p></span><span id="cesec80" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle90">MGMT immunoexpression and <span class="elsevierStyleItalic">MGMT</span> promoter methylation</span><p id="para160" class="elsevierStylePara elsevierViewall">The inverse relationship between MGMT immunoexpression and temozolomide response was first reported in two patients with aggressive pituitary adenomas (<a class="elsevierStyleCrossRef" href="#bib10">10</a>). The observation was subsequently confirmed by McCormack et al. who assessed MGMT immunoreactivity in a PRL cell carcinoma and an aggressive GH-producing adenoma (<a class="elsevierStyleCrossRef" href="#bib13">13</a>). In both studies, tumors with low-level MGMT immunoexpression demonstrated clinical and radiological responses to temozolomide therapy. Other authors have reported similar findings (<a class="elsevierStyleCrossRef" href="#bib51">51</a>). Thus, the demonstration of MGMT immunoreactivity appears to be useful for predicting the response of aggressive pituitary adenomas and carcinomas to temozolomide treatment.</p><p id="para170" class="elsevierStylePara elsevierViewall">The reports of Kovacs et al. (<a class="elsevierStyleCrossRef" href="#bib10">10</a>) and McCormack et al. (<a class="elsevierStyleCrossRef" href="#bib13">13</a>),(<a class="elsevierStyleCrossRef" href="#bib51">51</a>) underscore the inverse relationship between MGMT immunoexpression and the efficacy of temozolomide therapy, and this relationship has also been noted in high-grade gliomas (<a class="elsevierStyleCrossRefs" href="#bib46">46-48,52</a>). Whereas the standard method for evaluating <span class="elsevierStyleItalic">MGMT</span> status in gliomas is the identification of promoter methylation (<a class="elsevierStyleCrossRef" href="#bib47">47</a>), immunohistochemical detection of MGMT expression is an attractive alternative. It represents an inexpensive, readily accessible technology that is available to most laboratories (<a class="elsevierStyleCrossRef" href="#bib53">53</a>),(<a class="elsevierStyleCrossRef" href="#bib54">54</a>). Whereas most reports pertaining to gliomas and temozolomide therapy are based on promoter methylation status, data relating to pituitary neoplasms are based on MGMT immunoexpression (<a class="elsevierStyleCrossRef" href="#bib24">24</a>),(<a class="elsevierStyleCrossRef" href="#bib51">51</a>). Although several recent reports of aggressive pituitary tumors that were successfully treated with temozolomide have reported absent or low immunohistochemical expression of MGMT as a factor, one patient whose tumors exhibited higher levels of MGMT staining also experienced clinical improvement and tumor shrinkage following treatment (<a class="elsevierStyleCrossRef" href="#bib23">23</a>). It is of note that some tumors with no promoter methylation also respond to therapy (<a class="elsevierStyleCrossRef" href="#bib22">22</a>),(<a class="elsevierStyleCrossRef" href="#bib23">23</a>). These observations challenge the notion that <span class="elsevierStyleItalic">MGMT</span> promoter methylation is a reliable predictor of treatment response. Indeed, two recent studies on <span class="elsevierStyleItalic">MGMT</span> promoter methylation and the temozolomide response in eight aggressive adenomas and seven pituitary carcinomas found no association between promoter methylation status and response (<a class="elsevierStyleCrossRef" href="#bib22">22</a>),(<a class="elsevierStyleCrossRef" href="#bib23">23</a>). Salehi et al. (<a class="elsevierStyleCrossRef" href="#bib55">55</a>) did not find a close correlation between MGMT immunoexpression and <span class="elsevierStyleItalic">MGMT</span> promoter methylation in a study on aggressive pituitary adenomas and carcinomas. Thus, the utility of <span class="elsevierStyleItalic">MGMT</span> promoter methylation for the selection of patients who might respond well to temozolomide treatment remains controversial and an active focus of further research. The problem is that many tumors possess an admixture of MGMT immunopositive and immune-negative cells. Obviously, in such instances, it is difficult to predict overall the responsive to temozolomide.</p><p id="para180" class="elsevierStylePara elsevierViewall">To date, MGMT immunoexpression has been documented in 23 adenomas and 11 carcinomas. In 18 tumors, MGMT labeling was low and correlated with a good therapeutic response to temozolomide (14/18 cases). In eight instances, MGMT staining was intermediate: five tumors responded well and three did not. In eight patients with high MGMT immunoexpression, only one responded positively. Thus, tumors featuring low- and intermediate-level MGMT immunoexpression (<span class="elsevierStyleItalic">n</span> = 26), when compared with those with high MGMT immunoexpression (<span class="elsevierStyleItalic">n</span> = 8), showed a good response to temozolomide in 19/26 (73%) versus 1/8 (13%) cases (<span class="elsevierStyleItalic">p</span> = 0.0039; two-tailed Fisher's exact test).</p></span><span id="cesec90" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle100">Suggested indications for using temozolomide treatment</span><p id="para190" class="elsevierStylePara elsevierViewall">Based on the published cases and the reported response rates, temozolomide therapy can be recommended when other options fail, particularly in the following instances: (1) aggressive PRL-producing tumors that are resistant to bromocriptine or cabergoline and continue to grow after surgery and radiotherapy; (2) aggressive ACTH-producing tumors, especially Crooke cell and Nelson syndrome variants that cannot be cured by surgery and radiotherapy; (3) recurrent, clinically non-functional tumors exhibiting continued growth after repeated surgeries and radiotherapy; (4) pituitary carcinomas.</p><p id="para200" class="elsevierStylePara elsevierViewall">Temozolomide has been documented as valuable for the treatment of aggressive pituitary adenomas and carcinomas. The clinical and radiological responses are encouraging: 60% of aggressive adenomas and 69% of pituitary carcinomas respond well to treatment. An inverse correlation exists between MGMT immunoexpression and the therapeutic response to temozolomide. Based upon our literature review, a significant proportion of the adenohypophysial tumors that are responsive to temozolomide show low-level MGMT immunoexpression, whereas only one tumor showing high-level immunoexpression was found to respond. The use of immunohistochemistry for determining MGMT immunoexpression appears to be a promising guide for therapeutic decision-making (<a class="elsevierStyleCrossRef" href="#bib13">13</a>),(<a class="elsevierStyleCrossRef" href="#bib53">53</a>). Obviously, all available methods for assessing the likelihood of a positive temozolomide response should be utilized. We feel strongly that the determination of MGMT immunoreactivity is of clinical value and that <span class="elsevierStyleItalic">MGMT</span> promoter methylation status should be determined as well. The molecular mechanisms that affect <span class="elsevierStyleItalic">MGMT</span> expression remain to be fully elucidated. Targeted modulation of <span class="elsevierStyleItalic">MGMT</span> may be used in patients who may otherwise not respond to temozolomide therapy. Future therapies that incorporate different dosing regimens or other drugs may improve the tumor responsiveness.</p></span></span><span id="cesec100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle110">DISCLOSURE</span><p id="para210" class="elsevierStylePara elsevierViewall">The authors have no personal financial or institutional interest in any pharmaceutical agents or testing devices described herein.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:6 [ 0 => array:2 [ "identificador" => "xpalclavsec1581185" "titulo" => "KEYWORDS" ] 1 => array:3 [ "identificador" => "cesec10" "titulo" => "INTRODUCTION" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "cesec20" "titulo" => "Temozolomide" ] 1 => array:2 [ "identificador" => "cesec30" "titulo" => "Pituitary adenomas" ] 2 => array:2 [ "identificador" => "cesec40" "titulo" => "Pituitary carcinomas" ] 3 => array:2 [ "identificador" => "cesec50" "titulo" => "Morphological changes" ] ] ] 2 => array:3 [ "identificador" => "cesec60" "titulo" => "DISCUSSION" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "cesec70" "titulo" => "Response to treatment" ] 1 => array:2 [ "identificador" => "cesec80" "titulo" => "MGMT immunoexpression and MGMT promoter methylation" ] 2 => array:2 [ "identificador" => "cesec90" "titulo" => "Suggested indications for using temozolomide treatment" ] ] ] 3 => array:2 [ "identificador" => "cesec100" "titulo" => "DISCLOSURE" ] 4 => array:2 [ "identificador" => "xack638762" "titulo" => "ACKNOWLEDGMENTS" ] 5 => array:1 [ "titulo" => "REFERENCES" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "KEYWORDS" "identificador" => "xpalclavsec1581185" "palabras" => array:5 [ 0 => "Pituitary adenoma" 1 => "Pituitary carcinoma" 2 => "MGMT" 3 => "Temozolomide" 4 => "Review" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:1 [ "resumen" => "<span id="ceabs10" class="elsevierStyleSection elsevierViewall"><p id="spara10" class="elsevierStyleSimplePara elsevierViewall">Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. <span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span>-methylguanine-DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of <span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span>-methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level <span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span>-methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:1 [ "nota" => "<p class="elsevierStyleNotepara" id="cenpara10">No potential conflict of interest was reported.</p> <p class="elsevierStyleNotepara" id="cenpara20">Ortiz LD, Syro LV, Scheithauer BW, and Kovacs K conceived the study and wrote the manuscript. Ortiz LD, Syro LV, and Rotondo F searched the literature and extracted the data. Rotondo F, Uribe H, Fadul CE, and Horvath E contributed to the initial version of the manuscript. All authors contributed to the critical revision of the manuscript and approved the final version.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "REFERENCES" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "cebibsec10" "bibliografiaReferencia" => array:55 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of aggressive pituitary adenomas: current treatment strategies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => """ M Buchfelder \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Pituitary" "fecha" => "2009" "volumen" => "12" "numero" => "3" "paginaInicial" => "60" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical review: Diagnosis and management of pituitary carcinomas" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => """ GA Kaltsas \n \t\t\t\t\t\t\t\t """ 1 => """ P Nomikos \n \t\t\t\t\t\t\t\t """ 2 => """ G Kontogeorgos \n \t\t\t\t\t\t\t\t """ 3 => """ M Buchfelder \n \t\t\t\t\t\t\t\t """ 4 => """ AB Grossman \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2005" "volumen" => "90" "numero" => "5" "paginaInicial" => "99" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pituitary carcinomas" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ A Colao \n \t\t\t\t\t\t\t\t """ 1 => """ AS Ochoa \n \t\t\t\t\t\t\t\t """ 2 => """ RS Auriemma \n \t\t\t\t\t\t\t\t """ 3 => """ A Faggiano \n \t\t\t\t\t\t\t\t """ 4 => """ R Pivonello \n \t\t\t\t\t\t\t\t """ 5 => """ G Lombardi \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Front Horm Res" "fecha" => "2010" "volumen" => "38" "paginaInicial" => "108" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pituitary carcinoma: a clinicopathologic study of 15 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ PJ Pernicone \n \t\t\t\t\t\t\t\t """ 1 => """ BW Scheithauer \n \t\t\t\t\t\t\t\t """ 2 => """ TJ Sebo \n \t\t\t\t\t\t\t\t """ 3 => """ KT Kovacs \n \t\t\t\t\t\t\t\t """ 4 => """ E Horvath \n \t\t\t\t\t\t\t\t """ 5 => """ WF Young Jr \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cancer" "fecha" => "1997" "volumen" => "79" "numero" => "4" "paginaInicial" => "12" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8988721" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide: a novel treatment for pituitary carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => """ S Lim \n \t\t\t\t\t\t\t\t """ 1 => """ H Shahinian \n \t\t\t\t\t\t\t\t """ 2 => """ MM Maya \n \t\t\t\t\t\t\t\t """ 3 => """ W Yong \n \t\t\t\t\t\t\t\t """ 4 => """ AP Heaney \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2006" "volumen" => "7" "numero" => "6" "paginaInicial" => "20" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term response of pituitary carcinoma to temozolomide. Report of two cases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ CE Fadul \n \t\t\t\t\t\t\t\t """ 1 => """ AL Kominsky \n \t\t\t\t\t\t\t\t """ 2 => """ LP Meyer \n \t\t\t\t\t\t\t\t """ 3 => """ LS Kingman \n \t\t\t\t\t\t\t\t """ 4 => """ WB Kinlaw \n \t\t\t\t\t\t\t\t """ 5 => """ CH Rhodes \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3171/jns.2006.105.1.6" "Revista" => array:6 [ "tituloSerie" => "J Neurosurg" "fecha" => "2006" "volumen" => "105" "numero" => "4" "paginaInicial" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16874886" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ LV Syro \n \t\t\t\t\t\t\t\t """ 1 => """ H Uribe \n \t\t\t\t\t\t\t\t """ 2 => """ LC Penagos \n \t\t\t\t\t\t\t\t """ 3 => """ LD Ortiz \n \t\t\t\t\t\t\t\t """ 4 => """ CE Fadul \n \t\t\t\t\t\t\t\t """ 5 => """ E Horvath \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Endocrinol (Oxf)" "fecha" => "2006" "volumen" => "65" "numero" => "4" "paginaInicial" => "3" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ K Kovacs \n \t\t\t\t\t\t\t\t """ 1 => """ E Horvath \n \t\t\t\t\t\t\t\t """ 2 => """ LV Syro \n \t\t\t\t\t\t\t\t """ 3 => """ H Uribe \n \t\t\t\t\t\t\t\t """ 4 => """ LC Penagos \n \t\t\t\t\t\t\t\t """ 5 => """ LD Ortiz \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Hum Pathol" "fecha" => "2007" "volumen" => "38" "numero" => "1" "paginaInicial" => "9" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ LM Neff \n \t\t\t\t\t\t\t\t """ 1 => """ M Weil \n \t\t\t\t\t\t\t\t """ 2 => """ A Cole \n \t\t\t\t\t\t\t\t """ 3 => """ TR Hedges \n \t\t\t\t\t\t\t\t """ 4 => """ W Shucart \n \t\t\t\t\t\t\t\t """ 5 => """ D Lawrence \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Pituitary" "fecha" => "2007" "volumen" => "10" "numero" => "1" "paginaInicial" => "6" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ K Kovacs \n \t\t\t\t\t\t\t\t """ 1 => """ BW Scheithauer \n \t\t\t\t\t\t\t\t """ 2 => """ M Lombardero \n \t\t\t\t\t\t\t\t """ 3 => """ RE McLendon \n \t\t\t\t\t\t\t\t """ 4 => """ LV Syro \n \t\t\t\t\t\t\t\t """ 5 => """ H Uribe \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Acta Neuropathol" "fecha" => "2008" "volumen" => "115" "numero" => "2" "paginaInicial" => "2" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treating an aggressive prolactinoma in a patient with MEN 1: beneficial response to temozolomide" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ M Debono \n \t\t\t\t\t\t\t\t """ 1 => """ C Bridgewater \n \t\t\t\t\t\t\t\t """ 2 => """ R Ross \n \t\t\t\t\t\t\t\t """ 3 => """ J Newell-Price \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2213-8587(21)00177-7" "Revista" => array:5 [ "tituloSerie" => "Society for Endocrinology BES; Endocrine Abstracts" "fecha" => "2008" "volumen" => "15" "paginaInicial" => "188" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34332698" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of Nelson's syndrome with temozolomide" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ VJ Moyes \n \t\t\t\t\t\t\t\t """ 1 => """ G Alusi \n \t\t\t\t\t\t\t\t """ 2 => """ HI Sabin \n \t\t\t\t\t\t\t\t """ 3 => """ J Evanson \n \t\t\t\t\t\t\t\t """ 4 => """ DM Berney \n \t\t\t\t\t\t\t\t """ 5 => """ K Kovacs \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1530/EJE-08-0600" "Revista" => array:6 [ "tituloSerie" => "Eur J Endocrinol" "fecha" => "2009" "volumen" => "160" "numero" => "1" "paginaInicial" => "9" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18952762" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Low <span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span>-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ AI McCormack \n \t\t\t\t\t\t\t\t """ 1 => """ KL McDonald \n \t\t\t\t\t\t\t\t """ 2 => """ AJ Gill \n \t\t\t\t\t\t\t\t """ 3 => """ SJ Clark \n \t\t\t\t\t\t\t\t """ 4 => """ MG Burt \n \t\t\t\t\t\t\t\t """ 5 => """ KA Campbell \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2265.2008.03423.x" "Revista" => array:6 [ "tituloSerie" => "Clin Endocrinol (Oxf)" "fecha" => "2009" "volumen" => "71" "numero" => "2" "paginaInicial" => "33" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18803679" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of temozolomide in aggressive pituitary tumors: case report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => """ S Mohammed \n \t\t\t\t\t\t\t\t """ 1 => """ K Kovacs \n \t\t\t\t\t\t\t\t """ 2 => """ W Mason \n \t\t\t\t\t\t\t\t """ 3 => """ H Smyth \n \t\t\t\t\t\t\t\t """ 4 => """ MD Cusimano \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1227/01.NEU.0000335776.93176.83" "Revista" => array:6 [ "tituloSerie" => "Neurosurgery" "fecha" => "2009" "volumen" => "64" "numero" => "4" "paginaInicial" => "4" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19145153" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High incidence of low <span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span>-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ A Takeshita \n \t\t\t\t\t\t\t\t """ 1 => """ N Inoshita \n \t\t\t\t\t\t\t\t """ 2 => """ M Taguchi \n \t\t\t\t\t\t\t\t """ 3 => """ C Okuda \n \t\t\t\t\t\t\t\t """ 4 => """ N Fukuhara \n \t\t\t\t\t\t\t\t """ 5 => """ K Oyama \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Eur J Endocrinol" "fecha" => "2009" "volumen" => "161" "numero" => "4" "paginaInicial" => "9" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ C Hagen \n \t\t\t\t\t\t\t\t """ 1 => """ HD Schroeder \n \t\t\t\t\t\t\t\t """ 2 => """ S Hansen \n \t\t\t\t\t\t\t\t """ 3 => """ M Andersen \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Eur J Endocrinol" "fecha" => "2009" "volumen" => "161" "numero" => "4" "paginaInicial" => "7" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A novel use of temozolomide in a patient with malignant prolactinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => """ S Byrne \n \t\t\t\t\t\t\t\t """ 1 => """ C Karapetis \n \t\t\t\t\t\t\t\t """ 2 => """ N Vrodos \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Neurosci" "fecha" => "2009" "volumen" => "16" "numero" => "12" "paginaInicial" => "6" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ MS Thearle \n \t\t\t\t\t\t\t\t """ 1 => """ PU Freda \n \t\t\t\t\t\t\t\t """ 2 => """ JN Bruce \n \t\t\t\t\t\t\t\t """ 3 => """ SR Isaacson \n \t\t\t\t\t\t\t\t """ 4 => """ Y Lee \n \t\t\t\t\t\t\t\t """ 5 => """ RL Fine \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Pituitary" "fecha" => "2011" "volumen" => "14" "numero" => "4" "paginaInicial" => "24" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ LV Syro \n \t\t\t\t\t\t\t\t """ 1 => """ BW Scheithauer \n \t\t\t\t\t\t\t\t """ 2 => """ LD Ortiz \n \t\t\t\t\t\t\t\t """ 3 => """ CE Fadul \n \t\t\t\t\t\t\t\t """ 4 => """ E Horvath \n \t\t\t\t\t\t\t\t """ 5 => """ F Rotondo \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Hormones (Athens)" "fecha" => "2009" "volumen" => "8" "numero" => "4" "paginaInicial" => "6" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary. In press" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => """ E Morin \n \t\t\t\t\t\t\t\t """ 1 => """ F Berthelet \n \t\t\t\t\t\t\t\t """ 2 => """ J Weisnagel \n \t\t\t\t\t\t\t\t """ 3 => """ M Bidlingmaier \n \t\t\t\t\t\t\t\t """ 4 => """ O Serri \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1007/s11102-010-0232-9" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ H Bode \n \t\t\t\t\t\t\t\t """ 1 => """ M Seiz \n \t\t\t\t\t\t\t\t """ 2 => """ A Lammert \n \t\t\t\t\t\t\t\t """ 3 => """ MA Brockmann \n \t\t\t\t\t\t\t\t """ 4 => """ W Back \n \t\t\t\t\t\t\t\t """ 5 => """ HP Hammes \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Exp Clin Endocrinol Diabetes" "fecha" => "2010" "volumen" => "118" "numero" => "10" "paginaInicial" => "3" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ G Raverot \n \t\t\t\t\t\t\t\t """ 1 => """ N Sturm \n \t\t\t\t\t\t\t\t """ 2 => """ F de Fraipont \n \t\t\t\t\t\t\t\t """ 3 => """ M Muller \n \t\t\t\t\t\t\t\t """ 4 => """ S Salenave \n \t\t\t\t\t\t\t\t """ 5 => """ P Caron \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2010" "volumen" => "95" "numero" => "10" "paginaInicial" => "9" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with <span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span>-methylguanine methyltransferase (MGMT) promoter methylation and expression" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ ZM Bush \n \t\t\t\t\t\t\t\t """ 1 => """ JA Longtine \n \t\t\t\t\t\t\t\t """ 2 => """ T Cunningham \n \t\t\t\t\t\t\t\t """ 3 => """ D Schiff \n \t\t\t\t\t\t\t\t """ 4 => """ JA Jane Jr \n \t\t\t\t\t\t\t\t """ 5 => """ ML Vance \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2010" "volumen" => "95" "numero" => "11" "paginaInicial" => "90" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of pituitary neoplasms with temozolomide: a review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ LV Syro \n \t\t\t\t\t\t\t\t """ 1 => """ LD Ortiz \n \t\t\t\t\t\t\t\t """ 2 => """ BW Scheithauer \n \t\t\t\t\t\t\t\t """ 3 => """ R Lloyd \n \t\t\t\t\t\t\t\t """ 4 => """ Q Lau \n \t\t\t\t\t\t\t\t """ 5 => """ R Gonzalez \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cancer" "fecha" => "2011" "volumen" => "117" "numero" => "3" "paginaInicial" => "62" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ M Losa \n \t\t\t\t\t\t\t\t """ 1 => """ E Mazza \n \t\t\t\t\t\t\t\t """ 2 => """ MR Terreni \n \t\t\t\t\t\t\t\t """ 3 => """ A McCormack \n \t\t\t\t\t\t\t\t """ 4 => """ AJ Gill \n \t\t\t\t\t\t\t\t """ 5 => """ M Motta \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Eur J Endocrinol" "fecha" => "2010" "volumen" => "163" "numero" => "6" "paginaInicial" => "51" ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide for corticotroph pituitary adenomas refractory to standard therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ TH Dillard \n \t\t\t\t\t\t\t\t """ 1 => """ SH Gultekin \n \t\t\t\t\t\t\t\t """ 2 => """ JB Delashaw Jr \n \t\t\t\t\t\t\t\t """ 3 => """ CG Yedinak \n \t\t\t\t\t\t\t\t """ 4 => """ EA Neuwelt \n \t\t\t\t\t\t\t\t """ 5 => """ M Fleseriu \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Pituitary" "fecha" => "2011" "volumen" => "14" "numero" => "1" "paginaInicial" => "91" ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease: report of a case and literature review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ L Curtò \n \t\t\t\t\t\t\t\t """ 1 => """ ML Torre \n \t\t\t\t\t\t\t\t """ 2 => """ F Ferrau \n \t\t\t\t\t\t\t\t """ 3 => """ V Pitini \n \t\t\t\t\t\t\t\t """ 4 => """ G Altavilla \n \t\t\t\t\t\t\t\t """ 5 => """ F Granata \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Scientific World Journal" "fecha" => "2010" "volumen" => "10" "paginaInicial" => "8" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ M Murakami \n \t\t\t\t\t\t\t\t """ 1 => """ A Mizutani \n \t\t\t\t\t\t\t\t """ 2 => """ S Asano \n \t\t\t\t\t\t\t\t """ 3 => """ H Katakami \n \t\t\t\t\t\t\t\t """ 4 => """ Y Ozawa \n \t\t\t\t\t\t\t\t """ 5 => """ K Yamazaki \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1227/NEU.0b013e3182059e10" "Revista" => array:6 [ "tituloSerie" => "Neurosurgery" "fecha" => "2011" "volumen" => "68" "numero" => "6" "paginaInicial" => "7" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21304334" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ O Moshkin \n \t\t\t\t\t\t\t\t """ 1 => """ LV Syro \n \t\t\t\t\t\t\t\t """ 2 => """ BW Scheithauer \n \t\t\t\t\t\t\t\t """ 3 => """ LD Ortiz \n \t\t\t\t\t\t\t\t """ 4 => """ CE Fadul \n \t\t\t\t\t\t\t\t """ 5 => """ H Uribe \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Hormones (Athens)" "fecha" => "2011" "volumen" => "10" "numero" => "2" "paginaInicial" => "7" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ MF Stevens \n \t\t\t\t\t\t\t\t """ 1 => """ JA Hickman \n \t\t\t\t\t\t\t\t """ 2 => """ SP Langdon \n \t\t\t\t\t\t\t\t """ 3 => """ D Chubb \n \t\t\t\t\t\t\t\t """ 4 => """ L Vickers \n \t\t\t\t\t\t\t\t """ 5 => """ R Stone \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cancer Res" "fecha" => "1987" "volumen" => "47" "numero" => "22" "paginaInicial" => "52" ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemical approaches to the discovery and development of cancer therapies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => """ S Neidle \n \t\t\t\t\t\t\t\t """ 1 => """ DE Thurston \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Nat Rev Cancer" "fecha" => "2005" "volumen" => "5" "numero" => "4" "paginaInicial" => "96" ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Current and future developments in the use of temozolomide for the treatment of brain tumours" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ R Stupp \n \t\t\t\t\t\t\t\t """ 1 => """ M Gander \n \t\t\t\t\t\t\t\t """ 2 => """ S Leyvraz \n \t\t\t\t\t\t\t\t """ 3 => """ E Newlands \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2001" "volumen" => "2" "numero" => "9" "paginaInicial" => "60" ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ R Stupp \n \t\t\t\t\t\t\t\t """ 1 => """ WP Mason \n \t\t\t\t\t\t\t\t """ 2 => """ MJ van den Bent \n \t\t\t\t\t\t\t\t """ 3 => """ M Weller \n \t\t\t\t\t\t\t\t """ 4 => """ B Fisher \n \t\t\t\t\t\t\t\t """ 5 => """ MJ Taphoorn \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "N Engl J Med" "fecha" => "2005" "volumen" => "352" "numero" => "10" "paginaInicial" => "96" ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib34" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide in malignant gliomas: current use and future targets" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => """ JL Villano \n \t\t\t\t\t\t\t\t """ 1 => """ TE Seery \n \t\t\t\t\t\t\t\t """ 2 => """ LR Bressler \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cancer Chemother Pharmacol" "fecha" => "2009" "volumen" => "64" "numero" => "4" "paginaInicial" => "55" ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib35" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ MH Kulke \n \t\t\t\t\t\t\t\t """ 1 => """ K Stuart \n \t\t\t\t\t\t\t\t """ 2 => """ PC Enzinger \n \t\t\t\t\t\t\t\t """ 3 => """ DP Ryan \n \t\t\t\t\t\t\t\t """ 4 => """ JW Clark \n \t\t\t\t\t\t\t\t """ 5 => """ A Muzikansky \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2005.03.8836" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2006" "volumen" => "24" "numero" => "3" "paginaInicial" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16330663" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib36" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => """ SS Agarwala \n \t\t\t\t\t\t\t\t """ 1 => """ JM Kirkwood \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1634/theoncologist.5-suppl_1-51" "Revista" => array:6 [ "tituloSerie" => "Oncologist" "fecha" => "2000" "volumen" => "5" "numero" => "2" "paginaInicial" => "51" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10804092" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib37" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temozolomide for the treatment of metastatic melanoma: a systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => """ I Quirt \n \t\t\t\t\t\t\t\t """ 1 => """ S Verma \n \t\t\t\t\t\t\t\t """ 2 => """ T Petrella \n \t\t\t\t\t\t\t\t """ 3 => """ K Bak \n \t\t\t\t\t\t\t\t """ 4 => """ M Charette \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Oncologist" "fecha" => "2007" "volumen" => "12" "numero" => "9" "paginaInicial" => "23" ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib38" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ E Shacham-Shmueli \n \t\t\t\t\t\t\t\t """ 1 => """ A Beny \n \t\t\t\t\t\t\t\t """ 2 => """ R Geva \n \t\t\t\t\t\t\t\t """ 3 => """ A Blachar \n \t\t\t\t\t\t\t\t """ 4 => """ A Figer \n \t\t\t\t\t\t\t\t """ 5 => """ D Aderka \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2011" "volumen" => "29" "numero" => "10" "paginaInicial" => "5" ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib39" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ JL Clarke \n \t\t\t\t\t\t\t\t """ 1 => """ FM Iwamoto \n \t\t\t\t\t\t\t\t """ 2 => """ J Sul \n \t\t\t\t\t\t\t\t """ 3 => """ K Panageas \n \t\t\t\t\t\t\t\t """ 4 => """ AB Lassman \n \t\t\t\t\t\t\t\t """ 5 => """ LM DeAngelis \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2009" "volumen" => "27" "numero" => "23" "paginaInicial" => "7" ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib40" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mechanisms of disease: temozolomide and glioblastoma: look to the future" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => """ MM Mrugala \n \t\t\t\t\t\t\t\t """ 1 => """ MC Chamberlain \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Nat Clin Pract Oncol" "fecha" => "2008" "volumen" => "5" "numero" => "8" "paginaInicial" => "86" ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib41" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Targeted modulation of MGMT: clinical implications" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => """ L Liu \n \t\t\t\t\t\t\t\t """ 1 => """ SL Gerson \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Cancer Res" "fecha" => "2006" "volumen" => "12" "numero" => "2" "paginaInicial" => "31" ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib42" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "MGMT immunohistochemical expression and promoter methylation in human glioblastoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ FJ Rodriguez \n \t\t\t\t\t\t\t\t """ 1 => """ SN Thibodeau \n \t\t\t\t\t\t\t\t """ 2 => """ RB Jenkins \n \t\t\t\t\t\t\t\t """ 3 => """ KV Schowalter \n \t\t\t\t\t\t\t\t """ 4 => """ BL Caron \n \t\t\t\t\t\t\t\t """ 5 => """ P O'Neill B \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Appl Immunohistochem Mol Morphol" "fecha" => "2008" "volumen" => "16" "numero" => "1" "paginaInicial" => "65" ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib43" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical relevance of MGMT in the treatment of cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => """ SL Gerson \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2002" "volumen" => "20" "numero" => "9" "paginaInicial" => "99" ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib44" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inactivation of the DNA repair gene <span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span>-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => """ M Esteller \n \t\t\t\t\t\t\t\t """ 1 => """ SR Hamilton \n \t\t\t\t\t\t\t\t """ 2 => """ PC Burger \n \t\t\t\t\t\t\t\t """ 3 => """ SB Baylin \n \t\t\t\t\t\t\t\t """ 4 => """ JG Herman \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cancer Res" "fecha" => "1999" "volumen" => "59" "numero" => "4" "paginaInicial" => "7" ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib45" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ S Sharma \n \t\t\t\t\t\t\t\t """ 1 => """ F Salehi \n \t\t\t\t\t\t\t\t """ 2 => """ BW Scheithauer \n \t\t\t\t\t\t\t\t """ 3 => """ F Rotondo \n \t\t\t\t\t\t\t\t """ 4 => """ LV Syro \n \t\t\t\t\t\t\t\t """ 5 => """ K Kovacs \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Anticancer Res" "fecha" => "2009" "volumen" => "29" "numero" => "10" "paginaInicial" => "68" ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib46" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ M Esteller \n \t\t\t\t\t\t\t\t """ 1 => """ J Garcia-Foncillas \n \t\t\t\t\t\t\t\t """ 2 => """ E Andion \n \t\t\t\t\t\t\t\t """ 3 => """ SN Goodman \n \t\t\t\t\t\t\t\t """ 4 => """ OF Hidalgo \n \t\t\t\t\t\t\t\t """ 5 => """ V Vanaclocha \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "N Engl J Med" "fecha" => "2000" "volumen" => "343" "numero" => "19" "paginaInicial" => "4" ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib47" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "MGMT gene silencing and benefit from temozolomide in glioblastoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ ME Hegi \n \t\t\t\t\t\t\t\t """ 1 => """ AC Diserens \n \t\t\t\t\t\t\t\t """ 2 => """ T Gorlia \n \t\t\t\t\t\t\t\t """ 3 => """ MF Hamou \n \t\t\t\t\t\t\t\t """ 4 => """ N de Tribolet \n \t\t\t\t\t\t\t\t """ 5 => """ M Weller \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "N Engl J Med" "fecha" => "2005" "volumen" => "352" "numero" => "10" "paginaInicial" => "1003" ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib48" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "DNA mismatch repair and <span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span>-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ HS Friedman \n \t\t\t\t\t\t\t\t """ 1 => """ RE McLendon \n \t\t\t\t\t\t\t\t """ 2 => """ T Kerby \n \t\t\t\t\t\t\t\t """ 3 => """ M Dugan \n \t\t\t\t\t\t\t\t """ 4 => """ SH Bigner \n \t\t\t\t\t\t\t\t """ 5 => """ AJ Henry \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "1998" "volumen" => "16" "numero" => "12" "paginaInicial" => "7" ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib49" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ GA Kaltsas \n \t\t\t\t\t\t\t\t """ 1 => """ JJ Mukherjee \n \t\t\t\t\t\t\t\t """ 2 => """ PN Plowman \n \t\t\t\t\t\t\t\t """ 3 => """ JP Monson \n \t\t\t\t\t\t\t\t """ 4 => """ AB Grossman \n \t\t\t\t\t\t\t\t """ 5 => """ GM Besser \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "1998" "volumen" => "83" "numero" => "12" "paginaInicial" => "8" ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib50" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prolactin-producing pituitary adenoma and carcinoma with neuronal components: a metaplastic lesion" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ BW Scheithauer \n \t\t\t\t\t\t\t\t """ 1 => """ E Horvath \n \t\t\t\t\t\t\t\t """ 2 => """ K Kovacs \n \t\t\t\t\t\t\t\t """ 3 => """ RV Lloyd \n \t\t\t\t\t\t\t\t """ 4 => """ L Stefaneanu \n \t\t\t\t\t\t\t\t """ 5 => """ M Buchfelder \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Pituitary" "fecha" => "1999" "volumen" => "1(3-4)" "paginaInicial" => "205" ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib51" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => """ AI McCormack \n \t\t\t\t\t\t\t\t """ 1 => """ JA Wass \n \t\t\t\t\t\t\t\t """ 2 => """ AB Grossman \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Eur J Clin Invest" "fecha" => "2011" "volumen" => "41" "numero" => "10" "paginaInicial" => "48" ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib52" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span>-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ IF Pollack \n \t\t\t\t\t\t\t\t """ 1 => """ RL Hamilton \n \t\t\t\t\t\t\t\t """ 2 => """ RW Sobol \n \t\t\t\t\t\t\t\t """ 3 => """ J Burnham \n \t\t\t\t\t\t\t\t """ 4 => """ AJ Yates \n \t\t\t\t\t\t\t\t """ 5 => """ EJ Holmes \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2006" "volumen" => "24" "numero" => "21" "paginaInicial" => "7" ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib53" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleItalic">O</span><span class="elsevierStyleSup">6</span>-Methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ G Widhalm \n \t\t\t\t\t\t\t\t """ 1 => """ S Wolfsberger \n \t\t\t\t\t\t\t\t """ 2 => """ M Preusser \n \t\t\t\t\t\t\t\t """ 3 => """ A Woehrer \n \t\t\t\t\t\t\t\t """ 4 => """ MR Kotter \n \t\t\t\t\t\t\t\t """ 5 => """ T Czech \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cancer" "fecha" => "2009" "volumen" => "115" "numero" => "5" "paginaInicial" => "80" ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib54" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "MGMT immunoexpression in aggressive pituitary adenoma and carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ Q Lau \n \t\t\t\t\t\t\t\t """ 1 => """ B Scheithauer \n \t\t\t\t\t\t\t\t """ 2 => """ K Kovacs \n \t\t\t\t\t\t\t\t """ 3 => """ E Horvath \n \t\t\t\t\t\t\t\t """ 4 => """ LV Syro \n \t\t\t\t\t\t\t\t """ 5 => """ R Lloyd \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Pituitary" "fecha" => "2010" "volumen" => "13" "numero" => "4" "paginaInicial" => "79" ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib55" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ F Salehi \n \t\t\t\t\t\t\t\t """ 1 => """ BW Scheithauer \n \t\t\t\t\t\t\t\t """ 2 => """ JM Kros \n \t\t\t\t\t\t\t\t """ 3 => """ Q Lau \n \t\t\t\t\t\t\t\t """ 4 => """ M Fealey \n \t\t\t\t\t\t\t\t """ 5 => """ D Erickson \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Neurooncol" "fecha" => "2011" "volumen" => "104" "numero" => "3" "paginaInicial" => "57" ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack638762" "titulo" => "ACKNOWLEDGMENTS" "texto" => "<p id="para220" class="elsevierStylePara elsevierViewall">The authors are grateful to the Jarislowsky and Lloyd Carr Harris Foundation for their continued support. The authors thank Mrs. Denise Chase from the Mayo Clinic for her excellent assistance and secretarial support.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/18075932/00000067000000S1/v1_202212010649/S1807593222024061/v1_202212010649/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/18075932/00000067000000S1/v1_202212010649/S1807593222024061/v1_202212010649/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222024061?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 3 | 1 | 4 |
| 2024 October | 22 | 34 | 56 |
| 2024 September | 20 | 21 | 41 |
| 2024 August | 18 | 20 | 38 |
| 2024 July | 16 | 21 | 37 |
| 2024 June | 15 | 6 | 21 |
| 2024 May | 15 | 14 | 29 |
| 2024 April | 14 | 21 | 35 |
| 2024 March | 17 | 12 | 29 |
| 2024 February | 18 | 14 | 32 |
| 2024 January | 8 | 10 | 18 |
| 2023 December | 8 | 16 | 24 |
| 2023 November | 12 | 16 | 28 |
| 2023 October | 13 | 34 | 47 |
| 2023 September | 13 | 24 | 37 |
| 2023 August | 7 | 7 | 14 |
| 2023 July | 8 | 20 | 28 |
| 2023 June | 8 | 4 | 12 |
| 2023 May | 1 | 1 | 2 |
| 2023 April | 1 | 3 | 4 |
| 2023 March | 1 | 1 | 2 |
| 2023 February | 1 | 0 | 1 |
| 2023 January | 3 | 1 | 4 |
| 2022 December | 1 | 1 | 2 |
Show all